Foreign Trade Operator as Filing Applicant in Macao
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Article 11(2)(1) of Law No. 12/2025 provides that, for Class I or Class IIa medical devices, the filing application must be submitted by a foreign trade operator who meets the requirements of Article 11(1)(3) (not being in a period of supplementary penalty, supplementary sanction or security measure prohibiting an application for registration or filing). Article 21(3) of the implementing rules further provides that applicants that are holders of a manufacturing licence or foreign trade operators are not required to submit the materials listed in Article 21(2)(1) and (2) (applicant information, criminal record certificate and no-debt certificate). The foreign trade operator is both the key to the low-risk import channel and the basis for the simplified documentation set.
- Class I and Class IIa devices enter Macao, China through the filing channel, with a foreign trade operator as applicant.
- The foreign trade operator concept comes from Law No. 7/2003 and has no separate licence of its own.
- Foreign trade operators and manufacturing licence holders are exempt from two categories of administrative documents.
- Technical documents remain mandatory despite the exemption.
- Proof of overseas marketing remains a filing requirement that cannot be waived.
In practical terms, the foreign trade operator route determines how easily a low-risk portfolio enters Macao, China. Companies importing Class I and Class IIa devices should confirm at the outset who acts as the foreign trade operator, because the filing cannot be submitted without a qualifying applicant, and because the eligibility of that applicant directly determines whether the document exemptions of Article 21(3) of the implementing rules can be used.
2. Legal basis
The foreign trade operator pathway rests on the parent law and the implementing rules, and connects to the foreign trade regime established by Law No. 7/2003. The table below summarises the instruments and provisions cited in this article.
| Regulatory instrument | Reference | Publication date | Provisions |
| Medical Devices Regulatory Regime | Law No. 12/2025 (Official Gazette No. 30/2025) | Published on 28 July 2025; effective on 1 July 2026 | Article 11(1)(3); Article 11(2)(1) (filing of Class I and Class IIa devices by a foreign trade operator); Article 24 (medical devices subject to filing) |
| Implementing Rules of the Medical Devices Regulatory Regime | Administrative Regulation No. 11/2026 (Official Gazette No. 20/2026) | Published on 18 May 2026; effective on 1 July 2026 | Article 21(2)(1) and (2); Article 21(3) (exemption of documents for foreign trade operators); Article 23 (formality review of filing) |
| Foreign Trade Law | Law No. 7/2003 | Current version, verified as of 2026-10-29 | Provisions on foreign trade operators and on import licences |
| Industry promotional materials of the Drug Supervision Administration | Documents published by the ISAF | Current version, verified as of 2026-10-29 | Statements on the correspondence between filing entities and classification |
3. Expert insights
Insight one: the foreign trade operator is an existing legal concept, not a newly created status. The regime directly carries over the concept of foreign trade operator established under Law No. 7/2003, the Foreign Trade Law, without creating a separate licence for it. This contrasts with Class IIb and Class III devices, for which the applicant must be a business licence holder — the threshold for the subject qualifying for the low-risk channel is markedly lower. For companies building an import structure, this means the commercial decision of who holds the foreign trade operator status can be made independently of the medical device licensing decisions, since no additional device-specific licence is required for Class I and Class IIa filing.
Insight two: the scope of the document exemption covers items (1) and (2). Article 21(3) exempts two categories of administrative documents, namely applicant information and the criminal record certificate and no-debt certificate. Technical documents (items (3) and (4)) must still be submitted. What is exempted is the administrative burden, not the technical requirements.
Insight three: foreign trade operators must still satisfy the good-character requirement. Article 11(2)(1) makes reference to Article 11(1)(3), namely not being in a period of supplementary penalty, supplementary sanction or security measure prohibiting an application for registration or filing. Although no proof needs to be submitted on this point by virtue of Article 21(3), the substantive requirement remains in force, and the ISAF may verify it by other means.
Insight four: proof of overseas marketing must still be filed. Article 21(2)(4) makes reference to Article 10(2)(13) — the status of foreign trade operator does not waive the requirement of prior marketing in the country of origin. This is the single most demanding document in the low-risk channel. Its lead time is driven by foreign authorities rather than by the ISAF, so it should be ordered from the manufacturer as early as the import project is scoped.
Read together, these four points define the profile of the low-risk import route in Macao, China: a recognised applicant drawn from the existing foreign trade framework, a reduced set of administrative documents, a substantive good-character requirement that stays in force even where no proof is filed, and an unchanged obligation to evidence prior marketing in the country of origin. Companies that plan around this profile can prepare the filing dossier in parallel with their commercial arrangements instead of sequencing them one after the other.
4. Practical recommendations
- Identify the foreign trade operator before importing low-risk devices: without a qualifying applicant, no filing can be submitted.
- Submit in the capacity of a foreign trade operator: this removes the documents under items (1) and (2) and shortens preparation time.
- Obtain proof of overseas marketing early: it is the document in the filing that cannot be waived and has the longest lead time.
- Verify the status of the foreign trade operator: confirm that its qualification as a foreign trade operator is valid and that it is not in a prohibited period.
5. Verification checklist
- □ Confirmed that the device is Class I or Class IIa (filing applies)
- □ Qualified foreign trade operator identified
- □ Confirmed that the foreign trade operator is not in a period prohibiting application for registration or filing
- □ Exemption of documents under items (1) and (2) applied in accordance with Article 21(3)
- □ Proof of overseas marketing under item (13) obtained
- □ Technical documents under items (3) and (4) completed
Regulatory information verified as of 29 October 2026. The laws, guidelines and effective dates described in this article are limited to the content published by the official sources listed under Legal basis as of that date; where official documents are updated, the most recently published version prevails.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Macao, China. Our team coordinates local licence holder arrangements, import and supply requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us